7QQ7

Crystal structure of CYP142 from Mycobacterium tuberculosis in complex with an inhibitor at partial occupancy with PEG

7QQ7 の概要

• エントリーDOI: 10.2210/pdb7qq7/pdb
• 関連するPDBエントリー: 7P5T
• 分子名称: Steroid C26-monooxygenase, PROTOPORPHYRIN IX CONTAINING FE, ACETATE ION, ... (8 entities in total)
• 機能のキーワード: cyp, cytochrome, p450, inhibitor, tuberculosis, cholesterol, monooxygenase, oxidoreductase
• 由来する生物種: Mycobacterium tuberculosis H37Rv
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 45876.01

構造登録者

Snee, M.,Levy, C.,Kavanagh, M. (登録日: 2022-01-06, 公開日: 2023-01-18, 最終更新日: 2025-07-30)

主引用文献

Kavanagh, M.E.,McLean, K.J.,Gilbert, S.H.,Amadi, C.N.,Snee, M.,Tunnicliffe, R.B.,Arora, K.,Boshoff, H.I.M.,Fanourakis, A.,Rebollo-Lopez, M.J.,Ortega, F.,Levy, C.W.,Munro, A.W.,Leys, D.,Abell, C.,Coyne, A.G.
Fragment-Based Development of Small Molecule Inhibitors Targeting Mycobacterium tuberculosis Cholesterol Metabolism.
J.Med.Chem., 2025

PubMed Abstract: Tuberculosis is the deadliest infectious disease in history and new drugs are urgently required to combat multidrug-resistant (MDR) strains of (). Here, we exploit the relience of on host-derived cholesterol to develop a novel class of antitubercular compounds that target CYP125 and CYP142; the enzymes that catalyze the first step of cholesterol metabolism. A combination of fragment screening and structure-based drug design was used to identify a hit compound and guide synthetic optimization of a dual CYP125/142 ligand ( 40-160 nM), which potently inhibits enzyme activity in vitro ( < 100 nM), and the growth of in extracellular (MIC 0.4-1.5 μM) and intracellular assays (IC 1.7 μM). The structural data and lead compounds reported here will help study cholesterol metabolism and guide the development of novel antibiotics to combat MDR

PubMed: 40653654
DOI: 10.1021/acs.jmedchem.5c00478

実験手法

X-RAY DIFFRACTION (1.6 Å)